Document is current
Any future updates will be listed below
-
Authors
Albertini, Giulia https://orcid.org/0000-0002-8215-2432
Zielonka, Magdalena https://orcid.org/0000-0001-9641-9778
Cuypers, Marie-Lynn https://orcid.org/0000-0001-7540-389X
Snellinx, An
Xu, Ciana https://orcid.org/0009-0009-8280-1736
Poovathingal, Suresh
Wojno, Marta https://orcid.org/0000-0003-2711-1264
Davie, Kristofer https://orcid.org/0000-0003-2182-1249
van Lieshout, Veerle https://orcid.org/0000-0003-4033-4286
Craessaerts, Katleen
Wolfs, Leen
Pasciuto, Emanuela
Jaspers, Tom https://orcid.org/0000-0002-7485-4397
Horré, Katrien
Serneels, Lurgarde
Fiers, Mark
Dewilde, Maarten https://orcid.org/0000-0002-3138-281X
De Strooper, Bart https://orcid.org/0000-0001-5455-5819
- License Information
-
More Information
Article History
Received: 30 July 2024
Accepted: 9 October 2025
First Online: 24 November 2025
Competing interests
: B.D.S. has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies and is now a consultant to Muna Therapeutics. B.D.S. is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna Therapeutics. The other authors declare no competing interests.
